 WATERTOWN, Mass., March 02, 2022 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences: 